Tasos Katopodis/Getty Images News Shares of Emergent BioSolutions ( NYSE: EBS ) traded higher on Thursday after the company received a $67.4M order to supply the U.S.
government with Tembexa (brincidofovir), its smallpox therapy. The order was issued after the government exercised contract options to procure additional.
